key: cord-0296531-xqyeupez
authors: Ju, Y.; Lee, W. S.; Kelly, H. G.; Pilkington, E. H.; Wragg, K. M.; Subbarao, K.; Nguyen, T. H. O.; Rowntree, L. C.; Allen, L. F.; Bond, K.; Williamson, D.; Truong, N. P.; Plebanski, M.; Kedzierska, K.; Mahanty, S.; Caruso, F.; Wheatley, A. K.; Juno, J. A.; Kent, S.
title: Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine
date: 2022-01-10
journal: nan
DOI: 10.1101/2022.01.08.22268953
sha: 1891d03535e03857a8480aab21ab9e1d04417f37
doc_id: 296531
cord_uid: xqyeupez

Humans commonly have low level antibodies to poly(ethylene) glycol (PEG) due to environmental exposure. Lipid nanoparticle mRNA vaccines for SARS-CoV-2 contain small amounts of PEG but it is not known if PEG antibodies are enhanced by vaccination and if there are any consequences. We studied plasma from 55 people receiving the Comirnaty (Pfizer-BioNTech) mRNA vaccine for PEG-specific antibodies. Anti-PEG IgG was commonly detected prior to vaccination and was boosted a mean of 1.78-fold (range 0.68 to 16.6) by vaccination. Anti-PEG IgM increased 2.64-fold (0.76 to 12.84) following vaccination. PEG antibodies did not impact the neutralizing antibody response to vaccination. Pre-existing levels of anti-PEG IgM correlated with increased reactogenicity. A rise in PEG antibodies following vaccination was associated with an increase in the association of PEG-based nanoparticles to blood immune cells ex vivo. We conclude that low level PEG-specific antibodies can be modestly boosted by a lipid nanoparticle mRNA-vaccine and that PEG-specific antibodies are associated with higher reactogenicity. The longer-term clinical impact of the increase in PEG-specific antibodies induced by lipid nanoparticle mRNA-vaccines should be monitored.

4 observed after 2 vaccinations with a mean fold change of 1.78, range 0.68−16.6, across all 55 subjects. A rise in PEG-specific IgG was observed in 37 subjects (67%), mainly in those with pre-existing antibodies (35 subjects) (Fig. 1A, Supplementary Fig. 2A ). PEG-specific IgM antibodies also increased after vaccination with a mean fold change of 2.64, range 0.76−12.84, across all 55 subjects. Forty-one of the 55 subjects had a rise in PEG-specific IgM following 5 vaccination, including 11 who did not develop PEG-specific IgG responses. There were 9 (16%) and 23 (42%) of subjects who had a boost of anti-PEG IgG and IgM with more than 2-fold change after vaccination, respectively. A time course analysis showed that subjects with increased PEG antibody responses had a stepwise increase after the first and second vaccination ( Supplementary Fig. 3 ). PEG antibodies did not increase further out to 3 months in a subset of 10 subjects (n=10) where late post-vaccination samples were available ( Supplementary Fig. 3B ). As a control group, we studied plasma samples from 55 unvaccinated subjects across 2 separate cohorts (40 SARS-CoV-2 infected convalescent subjects and 15 healthy donors) over a 6-month period (subject details in Supplementary Fig. 4) . In contrast to the Comirnaty vaccinated group, anti-PEG IgG and IgM titres did not increase and overall slightly decreased over a 6-month 15 period with a mean fold change of 0.92 and 0.98, respectively, across the 55 unvaccinated control subjects ( Figure 1B, Supplementary Fig. 2B ).

The anti-PEG IgG response following Comirnaty vaccination was gender-and age-dependent.

Females had higher titres of pre-existing anti-PEG IgG than males (mean titre 1:74 vs. 1:35, Fig. 20 1C, left). This is consistent with previous findings and has been postulated to be related to greater exposure of females to PEG-containing cosmetic products.(3) Females had a higher rise of anti-PEG IgG after Comirnaty vaccination than males (mean fold change 2.12 vs. 1.19, Fig. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268953 doi: medRxiv preprint 1C, right). We found the age of donors was negatively correlated with the pre-existing levels and change in anti-PEG IgG after vaccination (Fig. 1D ). Younger subjects have been previously reported to have higher PEG-specific antibodies in a large serosurvey.(3) Younger age was also associated with a greater boost to anti-PEG IgG following Comirnaty vaccination than older subjects. We did not observe an influence of gender or age on the change in anti-PEG IgM after 5 vaccination although pre-existing anti-PEG IgM showed a negative correlation with age ( Supplementary Fig. 5) To determine whether the PEG antibodies detected specifically recognised the PEG-lipid or other synthetic lipid components of the Comirnaty vaccine, we assessed a subset of 18 vaccinees 10 where larger plasma samples were available for antibody response to the ALC-0159 (PEG-lipid), ALC-0315 (ionizable lipid), and DSPC (helper lipid) components of the Comirnaty vaccine. We found anti-human IgG that was specific to the ALC-0159 PEG-lipid increased in 10 out of 18 subjects studied (mean fold change 3.03, range 1−27.4, Fig. 2A ). The boost of PEG-lipidspecific IgG correlated with the increase of PEG-specific IgG from the same subjects detected 15 using a 40 kilodalton PEG (Fig.2B ). In contrast, the other lipid components, ALC-0315 and DSPC, elicited no antibody responses before or after vaccination (Fig. 2C ). Furthermore, a humanized monoclonal anti-PEG IgG was used to assess specificity to the synthetic lipid components of Comirnaty vaccine. We found the monoclonal anti-PEG IgG specifically recognised the ALC-0159 (PEG-lipid) and 40 kilodalton PEG in a concentration-dependent 20 manner, whilst it did not recognise ALC-0315 or DSPC (Fig. 2D ). Taken together, these results suggest antibody recognition of PEG in the PEG-lipid component of the Comirnaty vaccine occurs in vaccinees.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268953 doi: medRxiv preprint PEG is a hydrophilic compound commonly formulated with therapeutics to reduce non-specific immune clearance. Anti-PEG antibodies can reduce the bioavailability and efficacy of PEGcontaining therapeutics.(6) To determine the potential of anti-PEG antibodies induced by Comirnaty vaccination to promote immune-mediated clearance of nanomaterials containing 5 PEG, we used a previously developed ex vivo human blood immune cell-particle association assay (Experimental design shown in Fig. 3A ).(12) We first analysed the association of a fluorescently labelled PEG-based nanomaterial, a 100 nm PEGylated mesoporous silica particle termed PEG-MS (characterisation in Supplementary Fig. 6 ). The assay incubates nanoparticles for 1 hr with fresh primary human blood cells containing monocytes, granulocytes, and B cells in 10 the presence of plasma before and after Comirnaty vaccination and measures nanoparticle and immune cell association by flow cytometry (details in Methods, gating strategy shown in Supplementary Fig. 7) . The PEG-MS nanoparticles displayed a range of plasma donor-dependent association with immune cells, consistent with our previous findings.(13) Baseline levels of PEG IgG (rather than IgM) antibodies correlated with the association of PEG-MS nanoparticles with 15 primary human immune cells ex vivo, illustrating that PEG-specific antibodies influence the behaviour of PEGylated nanoparticles (Fig. 3B, Supplementary Fig. 8A ). The biggest dynamic range of association was with B cells, likely mediated by antibody-mediated attachment to B cell complement receptors since heat inactivation of plasma has previously been shown to inhibit this association. (14) We found that there was an increase in the association of PEG-MS particles with 20 B cells when plasma was obtained after vaccination (Fig. 3D, left) . The degree of increase in anti-PEG IgM antibodies after vaccination correlated with the increase in association of PEG-MS particles to B cells (Fig. 3D, right) . In contrast, changes in monocyte or granulocyte association . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 10, 2022. 20 Plasma proteins are known to opsonize foreign nanomaterials in the blood, forming so-called "protein corona",(15-17) which leads to recognition and inactivation of nanomaterials by immune system.(18-21) In our previous studies, we found that the enrichment of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268953 doi: medRxiv preprint immunoglobulins in protein coronas is correlated with donor-specific nanoparticle association with human blood immune cells. (13) The studies herein demonstrate that anti-PEG antibodies are key immunoglobulins that drive the person-specific immune cell association of PEGcontaining nanoparticles in human blood. There has been speculation that anti-PEG antibody responses may be involved in reactogenicity 20 and anaphylaxis associated with COVID-19 lipid mRNA nanoparticle vaccination. Fig. 1,12,13) and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ; its association with anti-PEG antibodies. Reactogenicity was scored as the sum of local and systemic adverse events. Vaccine reactions were generally mild and no subjects experienced anaphylaxis or myocarditis in our small cohort. As previously reported, reactogenicity was higher after the second Comirnaty vaccination.(28) We found no association between vaccine reactogenicity and the pre-existing levels of anti-PEG IgG or the increased levels of anti-PEG 5 antibodies ( Supplementary Fig. 11 ). However, we found that the pre-existing anti-PEG IgM levels correlated with a higher rate of reactogenicity after both the first and second vaccinations (Fig. 4B) . Larger studies are required to confirm these data and to determine if changes in reactogenicity are associated with the modest induction or boosting of anti-PEG antibodies following future regimens utilizing further doses. 10 We conclude that low level PEG-specific IgG and IgM antibody responses are modestly but significantly boosted by the PEG-lipid contained in the Comirnaty SARS-CoV-2 lipid nanoparticle vaccine. PEG-specific antibodies present prior to or following vaccination did not negatively impact the immune response to 2 doses of the vaccine. However, even the small boost 15 of anti-PEG antibodies detected following vaccination was found to impact the association of PEGylated nanomedicines with monocytes, granulocytes and B cells ex vivo. This suggests it will be important to assess the impact of lipid nanoparticle vaccination on the biology of other PEGylated medicines. Importantly, higher pre-existing anti-PEG IgM levels were found to correlate with higher reactogenicity of the vaccine. Larger and longer studies are needed to 20 analyze the longer-term impact of boosting anti-PEG antibodies by lipid nanoparticle mRNA vaccination. Booster doses of SARS-CoV-2 lipid nanoparticle mRNA vaccines, now commonly recommended to enhance immunity(29) and for emerging variants of SARS-CoV-2,(30) as well . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268953 doi: medRxiv preprint as new mRNA lipid nanoparticle vaccines and therapies for other infectious diseases or cancers(31) may further increase PEG-specific antibodies. Generating next-generation lipid nanoparticles with alternatives to PEG(32) may be useful for overcoming PEG immunogenicity in the future.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268953 doi: medRxiv preprint

Supplementary Fig. 1 Supplementary Fig. 2 The impact of Comirnaty vaccination on the levels of PEG specific antibodies. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268953 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268953 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ;

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. ;

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 10, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 10, 2022. ; https://doi.org/10.1101/2022.01.08.22268953 doi: medRxiv preprint

Clinical relevance of pre-existing and treatment-induced anti-poly(ethylene glycol) antibodies

The dawn of mRNA vaccines: The covid-19 case

Mrna-lipid nanoparticle covid-19 vaccines: Structure and stability

Influence of poly(ethylene glycol) molecular architecture on particle assembly and ex vivo particle-immune cell interactions in human blood

Person-specific biomolecular coronas modulate nanoparticle interactions with immune cells in human blood

Link between low-fouling and stealth: A whole blood 15 biomolecular corona and cellular association analysis on nanoengineered particles

Biomolecular coronas provide the biological identity of nanosized materials

Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment

Biological identity of nanoparticles in vivo: Clinical implications of the protein corona

Interplay of protein corona and immune cells controls blood residency of liposomes

Neutralizing antibody levels are highly 10 predictive of immune protection from symptomatic sars-cov-2 infection

Suspicions grow that nanoparticles in pfizer's covid-19 vaccine trigger rare allergic reactions

Potential mechanisms of anaphylaxis to covid-19 mRNA vaccines

We thank all the dedicated participants involved in the studies. We thank Thakshila Amarasena, Helen Kent, Jeni Mitchell, Chioma Uzoho, Barbara Scher, Dilini Rathnayake, Honghua Ding and Louise Randall for expert assistance.